M&A Healthcare Advisors is pleased to present a URAC, ACHC, PCAB, NABP accredited independent specialty pharmacy with multiple locations in California and Texas that is currently licensed in all 50 states. Most of the dispensing is closed-door specialty medications. However, there are community pharmacies available for in-store pick-up. The company has long-standing relationships with local health plans, servicing patients with a therapy focus on Transplant and HIV medications. The pharmacy is fully equipped for Non-Sterile Compounding and operates in compliance with USP chapters 795 (Non-Sterile) and 800 (Hazardous Drugs). M&A Healthcare Advisors (“MAHA”) has been engaged as the exclusive advisor to explore a complete sale of the Company.
In 2021, the pharmacy served a total of 8,539 active patients and 89,136 unique scripts (first fills). The Company generated a combined Revenue of $89.7 million and a Gross Profit of $10.7 million with an adjusted EBITDA of $2.2 million. Although sales have increased since 2020, the Gross Profit and subsequent Net Profit experienced a slight decrease year-over-year due to price increases, as well as maintaining larger operations teams to implement their planned growth strategy, including an expansion into new markets and continued focus on low-margin therapies for their California patients.
There are a total of 56 personnel within the company, including a full suite of senior management overseeing the various entities within the Company. Each pharmacy has a PIC. Except for the current owner, who is not involved in the day-to-day operations, all management personnel plan to stay and would like to be part of the future growth strategy. Ownership is selling to retire but committed to seeing that the company remains successful moving forward.